/ News

Global AMR R&D Hub hosts R&D modelling roundtable discussion

On October 27, 2019 the Global AMR R&D Hub convened currently active groups undertaking work modelling the development process for antibiotics. This small technical roundtable discussion was held in Berlin and facilitated a valuable exchange between expertise globally. The opportunity to better understand each other’s work, compare notes and discuss shared challenges was valuable as both these groups, and the Global AMR R&D Hub, progress with their work in understanding development realities and resource constraints in this field.  

Global AMR R&D Hub at World Health Summit

On October 27, 2019 the Secretariat Lead of the Global AMR R&D Hub Dr Elmar Nimmesgern participated in a panel discussion ‘Antimicrobial Resistance’ at the World Health Summit. www.worldhealthsummit.org
The direct link to the session is:
https://www.conference.worldhealthsummit.org/Program/Session/WHS2019/PD-03
The AMR theme has been addressed by several other sessions at the World Health Summit, highlighting the importance of tackling this issue.

India joins the Global AMR R&D Hub

With India joining, the global partnership working to address challenges and improve coordination and collaboration in AMR R&D is expanded. Membership now consists of 16 countries, the European Commission, 2 philanthropic foundations and 4 international organisations (as observers).

Global AMR R&D Hub at EU-JAMRAI 2nd Annual Meeting & Stakeholder Forum

On September 16-17, 2019 the Secretariat of the Global AMR R&D Hub was represented at the Stakeholder Forum of the EU Joint Action Antimicrobial Resistance and Healthcare-Associated Infections (EU JAMRAI) in Rome: https://eu-jamrai.eu/eu-jamrai-second-annual-meeting/
The Secretariat Lead, Dr Elmar Nimmesgern, participated in the round-table discussion on Economic models for stimulating innovation and access to antimicrobials. In the discussion he highlighted the importance of framing the discussion on incentives for antibiotics, both new and old, with concrete examples.
Dr Nimmesgern also led a workshop discussion on the antibiotics debate in Germany at the MSD Health Forum 2019 in Munich. There he suggested that discussions in Germany on assuring availability of innovative antibiotics and incentives for R&D may be relevant for other countries and there would be benefit in considering how the German approaches could be put into an international context and communicated more transparently.